Vivid Bioinnovations, PBC

Vivid Bioinnovations, PBC, a for-profit biotech company based in San Francisco, California, operates as a federal grant recipient focused on research and development of microfluidic and spatial genomics platforms for infectious disease diagnostics, cell therapy screening, and single-cell profiling applications. The vendor competes exclusively under small business set-asides, specifically the Small Business Innovation Research (SBIR) program across National Institutes of Health component agencies.

Vivid Bioinnovations delivers concrete capabilities in precision fluid handling, droplet microfluidics, spatial barcoding, and mass spectrometry integration for high-throughput biological screening and diagnostics. Recent grant work includes a $1.6 million National Institute on Aging Phase II SBIR award (completion August 2028) to commercialize FIND-SEQ, a cell sorting technology isolating rare cells based on DNA or RNA markers without surface markers, with application to neurodegenerative disease research; a $299.9 thousand National Institute of Allergy and Infectious Diseases Phase I SBIR award (completed July 2024) for multiplexed droplet digital nucleic acid amplification for HIV diagnosis; and a $300 thousand National Institute of General Medical Sciences award (completion July 2027) for an integrated micro-robotic screening platform combining nanoliter droplet dispensing, nanowell arrays, and MALDI mass spectrometry for high-throughput chemical reaction optimization and machine learning model training. Additional recent work spans a $306.9 thousand National Cancer Institute Phase II SBIR award (completion July 2027) for CAGES, a platform screening millions of CAR-T and cancer cell interactions in parallel at single-cell resolution, and two 2026 National Institute of Allergy and Infectious Diseases awards totaling $607.1 thousand for spatial genomics platforms and HIVE-SEQ, a single-cell multi-omics platform profiling intact HIV proviral genomes alongside host transcriptomes and proteomes.

All customer relationships concentrate within the National Institutes of Health; the National Institute of Allergy and Infectious Diseases holds five awards totaling $2.9 million in combined potential value, the National Institute of General Medical Sciences holds four awards, the National Institute on Aging holds two awards, and the National Cancer Institute holds one award. The vendor operates exclusively as a prime recipient on all twelve awards in the source data, with no subcontractor footprint. Activity has grown modestly from two awards in 2021 to four in 2026, with six awards (100% of the portfolio's potential value) reaching completion within the next twenty-four months and therefore facing renewal or recompete pressure. SCI-reported invoiced revenue on federal service contracts captures only $99 thousand in FY2025 across 0.3 FTEs at a median government-paid rate of $173.01 per hour; this narrow SCI footprint reflects Vivid Bioinnovations' concentration in research grants rather than service contracts, and does not represent the vendor's total federal or enterprise revenue.